SEP-225289
Total Payments
$2.4M
Transactions
735
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $200,000 | 1 | 1 |
| 2019 | $2.2M | 716 | 2 |
| 2018 | $37,741 | 16 | 0 |
| 2017 | $3,400 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 732 | 91.5% |
| Grant | $200,000 | 1 | 8.3% |
| Consulting Fee | $3,400 | 2 | 0.1% |
Payments by Type
Research
$2.2M
732 transactions
General
$203,400
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Dasotraline Binge Eating Disorder Extension Study | Sunovion Pharmaceuticals Inc. | $2.0M | 2 |
| A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder | Sunovion Pharmaceuticals Inc. | $157,863 | 0 |
| SEP-225289 | Sunovion Pharmaceuticals Inc. | $37,741 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 4
- Transactions 735
About SEP-225289
SEP-225289 is a drug associated with $2.4M in payments to 4 healthcare providers, recorded across 735 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $200,000 was paid across 1 transactions to 1 doctors.
The most common payment nature for SEP-225289 is "Unspecified" ($2.2M, 91.5% of total).
SEP-225289 is associated with 3 research studies, including "Dasotraline Binge Eating Disorder Extension Study" ($2.0M).